The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast.
Loading...
Issue Date
2024-02-23
Authors
Pandithar, Sneha*
Galke, Daniel*
Akume, Ahone*
Belyakov, Artem*
Lomonaco, Dominick*
Guerra, Amirah A*
Park, Jay*
Reff, Olivia*
Jin, Kideok
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
Background: ER positive breast cancer is currently targeted using various endocrine therapies. Despite the proven therapeutic efficacy, resistance to the drug and reoccurrence of tumor appears to be a complication that many patients deal with. Molecular pathways underlying the development of resistance are being widely studied.
Methods and results: In this study, using four established endocrine resistant breast cancer (ERBC) cell lines, we characterized CXCL1 as a secreted factor in crosstalk between ERBC cells and fibroblasts. Protein array revealed upregulation of CXCL1 and we confirmed the CXCL1 expression by real-time qRT-PCR and U-Plex assay. Co-culturing ERBC cells with fibroblasts enhanced the cell growth and migration compared to monoculture. The crosstalk of ERBC cells with fibroblasts significantly activates ERK/MAPK signaling pathway while reparixin, CXCR1/2 receptor inhibitor, attenuates the activity. Reparixin displayed the ERBC cell growth inhibition and the combination treatment with reparixin and CDK4/6 inhibitor (palbociclib and ribociclib) increased these inhibitory effect.
Conclusions: Taken together, our study implicates CXCL1 as a critical role in ERBC growth and metastasis via crosstalk with fibroblast and cotargeting CXCR1/2 and CDK4/6 could potentially overcome endocrine resistant breast cancer.
Citation
Pandithar S, Galke D, Akume A, Belyakov A, Lomonaco D, Guerra AA, Park J, Reff O, Jin K. The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast. Mol Biol Rep. 2024 Feb 23;51(1):331. doi: 10.1007/s11033-023-09119-4. PMID: 38393465; PMCID: PMC10891235.
ACPHS Research Commons URI
Description
Grants
R15 CA271221/CA/NCI NIH HHS/United States , 1R15CA271221-01A1/NH/NIH HHS/United States